What are the recommended adult dosing, dose adjustments for hepatic or renal impairment, contraindications, and common adverse effects of duloxetine?

Duloxetine: Adult Dosing, Adjustments, Contraindications, and Adverse Effects

Standard Adult Dosing by Indication

For diabetic peripheral neuropathic pain, start duloxetine at 60 mg once daily; doses above 60 mg provide no additional benefit and increase adverse events. 1, 2

• Diabetic neuropathy: 60 mg once daily is the target dose; 120 mg daily offers no additional efficacy and is less well tolerated 1, 2, 3
• Fibromyalgia: Begin at 30 mg once daily for 1 week, then increase to 60 mg once daily; doses >60 mg/day show no further benefit and higher adverse event rates 1, 4
• Chronic musculoskeletal pain (osteoarthritis, chronic low back pain): Start at 30 mg once daily for 1 week, then escalate to 60 mg once daily; higher doses do not improve outcomes 1, 5, 4
• Major depressive disorder and generalized anxiety disorder: Initiate at 30–40 mg daily, titrate to 60 mg once daily; some patients may require up to 120 mg daily in divided doses, though this is rarely necessary 1, 6

Maximum Dose Ceiling

• The FDA-approved maximum is 120 mg/day, but the recommended ceiling for pain indications is 60 mg/day to maintain optimal benefit-risk balance. 4, 1
• If no response occurs after 4–8 weeks at 60 mg daily, consider switching to pregabalin (300–600 mg/day) or gabapentin (1800–3600 mg/day) rather than escalating duloxetine beyond 60 mg 5, 2

---

Dose Adjustments for Hepatic and Renal Impairment

Avoid duloxetine entirely in patients with chronic liver disease, cirrhosis, or severe renal impairment (GFR <30 mL/min). 1

• Hepatic impairment: Duloxetine is contraindicated in any degree of chronic liver disease or cirrhosis due to risk of hepatotoxicity 1, 2
• Severe renal impairment (GFR <30 mL/min or dialysis-dependent): Avoid use; plasma concentrations of duloxetine and its metabolites accumulate significantly 1
• Mild to moderate renal impairment: Consider a lower starting dose (e.g., 30 mg once daily) and gradual titration, as diabetes frequently complicates renal function 1

---

Contraindications

Duloxetine is absolutely contraindicated with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome. 1, 5

• MAOIs: Allow ≥14 days after stopping an MAOI before starting duloxetine; allow ≥5 days after stopping duloxetine before starting an MAOI 1
• Linezolid or intravenous methylene blue: Do not initiate duloxetine in patients receiving these agents; if urgent treatment with linezolid/methylene blue is required in a patient on duloxetine, stop duloxetine promptly and monitor for serotonin syndrome for 5 days or 24 hours after the last dose of linezolid/methylene blue, whichever comes first 1
• Chronic liver disease or cirrhosis: Absolute contraindication 1
• Severe renal impairment (GFR <30 mL/min): Absolute contraindication 1
• Uncontrolled narrow-angle glaucoma: Duloxetine may precipitate angle-closure glaucoma 1

---

Common Adverse Effects

Nausea is the most frequent adverse effect (16–38% of patients), occurring predominantly in the first week; starting at 30 mg daily for 1 week before escalating to 60 mg significantly reduces this risk. 5, 7, 6

Gastrointestinal Effects

• Nausea (most common; dose-dependent) 5, 7, 6
• Dry mouth 5, 7
• Constipation 5, 7
• Diarrhea 5, 7

Neurological Effects

• Dizziness 5, 7
• Headache 5, 7
• Fatigue and somnolence 5, 7
• Insomnia 5

Other Common Effects

• Hyperhidrosis (excessive sweating) 5
• Decreased appetite 5
• Blurred vision 5

Cardiovascular Effects

• Mild increases in systolic and diastolic blood pressure and heart rate; monitor regularly, especially when combining with NSAIDs 5, 6, 8

---

Serious but Rare Adverse Effects

Discontinuation syndrome occurs in >1% of patients when duloxetine is stopped abruptly; always taper gradually over ≥2–4 weeks after >3 weeks of therapy. 5, 1

• Discontinuation syndrome: Dizziness, headache, nausea, paresthesia, irritability, anxiety, insomnia, hyperhidrosis, fatigue; taper over ≥2–4 weeks to minimize 5, 1
• Serotonin syndrome: Life-threatening when combined with other serotonergic agents (SSRIs, SNRIs, tramadol, meperidine, methadone, fentanyl, dextromethorphan, St. John's wort); presents with mental status changes, neuromuscular hyperactivity, autonomic instability 5, 9
• Suicidal ideation: Increased risk in children, adolescents, and young adults during initial weeks of treatment; close monitoring required 5
• Hepatotoxicity: Rare cases of severe liver injury; avoid in any hepatic impairment 5, 2
• Hyponatremia/SIADH: Geriatric patients and those on diuretics are at higher risk; presents with headache, confusion, weakness, unsteadiness, falls 1
• Urinary hesitation and retention: May require catheterization in severe cases 1
• QT-interval prolongation: Risk increases when combined with other QT-prolonging drugs 5

---

Key Drug Interactions

Never combine duloxetine with MAOIs, tramadol, or other serotonergic agents without close monitoring for serotonin syndrome. 5, 1

• MAOIs: Absolute contraindication 1
• Other antidepressants (SSRIs, SNRIs, TCAs): Heightened serotonin syndrome risk 5
• Serotonergic opioids (tramadol, meperidine, methadone, fentanyl): Increased serotonin toxicity and sedation 5
• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): May increase duloxetine levels 5, 7
• CYP2D6 substrates: Duloxetine is a moderate CYP2D6 inhibitor; dose reductions may be needed for drugs metabolized by this pathway 5, 8
• NSAIDs, aspirin, anticoagulants: Increased bleeding risk, particularly gastrointestinal; use cautiously 5
• Cannabis/cannabinoids: Inhibit CYP1A2, potentially increasing duloxetine levels and hepatotoxicity risk; start cannabis at lowest dose if duloxetine is established, monitor liver enzymes within 2 months if using CBD products 5

---

Special Populations and Monitoring

In geriatric patients with generalized anxiety disorder, start at 30 mg once daily for 2 weeks before increasing to 60 mg daily. 1

• Geriatric patients: Increased risk of hyponatremia, falls, cognitive impairment, and drug-drug interactions; cautious dose escalation recommended 10, 5, 1
• Diabetes patients: Duloxetine may cause small increases in fasting blood glucose and HbA1c (mean increase 0.5% vs 0.2% with routine care over 52 weeks); monitor glycemic control 1
• Cardiovascular disease: Monitor blood pressure and heart rate; use caution when combining with NSAIDs 5, 6
• Pregnancy: Contraindicated; women of reproductive potential must use reliable contraception 10

---

Clinical Pitfalls to Avoid

• Do not exceed 60 mg/day for pain indications (diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain); higher doses offer no additional benefit and increase adverse events 4, 1, 2
• Do not start at 60 mg daily; begin at 30 mg for 1 week to reduce nausea and improve tolerability 5, 1, 7
• Do not stop abruptly; taper over ≥2–4 weeks to prevent discontinuation syndrome 5, 1
• Do not use in hepatic impairment or severe renal impairment (GFR <30 mL/min); these are absolute contraindications 1
• Do not combine with MAOIs, linezolid, or methylene blue without appropriate washout periods or urgent monitoring protocols 1
• Do not assume all patients require 120 mg/day; most achieve adequate response at 60 mg daily within 4–6 weeks 5, 4